Santos-Juanes Galache, R.; Reyes García, S.; Carrero Martín, J.; Nuñez Domínguez, Á.; López Pando, M.; Álvarez Losada, I.; de la Fuente Villaverde, I.; Lozano-Blazquez, A.; Salgueiro, E.; Bordallo, J.;
et al. Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use. Life 2025, 15, 789.
https://doi.org/10.3390/life15050789
AMA Style
Santos-Juanes Galache R, Reyes García S, Carrero Martín J, Nuñez Domínguez Á, López Pando M, Álvarez Losada I, de la Fuente Villaverde I, Lozano-Blazquez A, Salgueiro E, Bordallo J,
et al. Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use. Life. 2025; 15(5):789.
https://doi.org/10.3390/life15050789
Chicago/Turabian Style
Santos-Juanes Galache, Raquel, Sebastian Reyes García, Jimena Carrero Martín, Álvaro Nuñez Domínguez, Marta López Pando, Irene Álvarez Losada, Irene de la Fuente Villaverde, Ana Lozano-Blazquez, Esther Salgueiro, Javier Bordallo,
and et al. 2025. "Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use" Life 15, no. 5: 789.
https://doi.org/10.3390/life15050789
APA Style
Santos-Juanes Galache, R., Reyes García, S., Carrero Martín, J., Nuñez Domínguez, Á., López Pando, M., Álvarez Losada, I., de la Fuente Villaverde, I., Lozano-Blazquez, A., Salgueiro, E., Bordallo, J., Santos-Juanes, J., & Galache Osuna, C.
(2025). Real-World Study of Tildrakizumab Survival in Psoriasis: Impact of Arthritis, Hypertension, and Prior Biologic Use. Life, 15(5), 789.
https://doi.org/10.3390/life15050789
